Clinical efficacy of inhaler devices containing β2-agonist bronchodilators in the treatment of asthma: Cochrane systematic review and meta-analysis of more than 100 randomized, controlled trials

American Journal of Respiratory Medicine

Volumn 2, Issue 4, 2003, Pages 349-365

  Ram, Felix S F ^a  

^a ROYAL COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHLOROFLUOROCARBON; CORTICOSTEROID; FENOTEROL; FLUORINATED HYDROCARBON; ISOPRENALINE; ORCIPRENALINE; PIRBUTEROL; REPROTEROL; RIMITEROL; SALBUTAMOL; TERBUTALINE;

ASTHMA; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUSTRY; DRY POWDER; FORCED EXPIRATORY VOLUME; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; META ANALYSIS; METERED DOSE INHALER; PATIENT CARE; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0041885342     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256663     Document Type: Review

References (130)

1. BTS. BTS guidelines for the management of chronic obstructive pulmonary disease: The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52 Suppl. 5: S1-S28
2. Newman SP, Pavia D, Moren F, et al. Deposition of pressurised aerosols in the human respiratory tract. Thorax 1981; 36 (1): 52-5
3. Newman SP. A comparison of lung deposition patterns between different asthma inhalers. J Aerosol Med 1995; 8 Suppl. 3: S21-6
4. Crompton GK. The adult patients difficulties with inhalers. Lung 1990; 169 Suppl.: 658-62
5. Larsen JS, Hahn M, Ekholm B, et al. Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. J Asthma 1994; 31 (3): 193-9
6. van Beerendonk I, Mesters I, Mudde AN, et al. Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device. J Asthma 1998; 35 (3): 273-9
7. North of England Asthma Guideline Development Group. North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care and management of asthma in adults. BMJ 1996; 312 (7033): 762-6
8. Ruggins NR, Milner AD, Swarbrick A. An assessment of a new breath actuated inhaler device in acutely wheezy children. Arch Dis Child 1993; 68 (4): 477-80
9. Newman SP, Weisz AW, Talaee N, et al. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991; 46 (10): 712-6
10. Pedersen S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 1986; 41 (2): 118-24
11. de Boer AH, Gjaltema D, Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers: part 2. effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int J Pharm 1996; 138: 45-56
12. Coldiron BM. Thinning of the ozone layer: facts and consequences. J Am Acad Dermatol 1992; 27 (5 Pt 1): 653-62
13. Barry PW, O'Callaghan C. In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices. Eur Respir J 1997; 10 (6): 1345-8
14. Desager KN, van Bever HP, Vermeire PA. Comparison of non-chlorofluorocarbon-containing salbutamol and conventional inhaler. Lancet 1996; 348 (9021): 200-1
15. Clark DJ, Clark RA, Lipworth BJ. Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. Thorax 1996; 51 (9): 941-3
16. Ram FS, Brocklebank DM, Muers M, et al. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2002: CD002170
17. Ram FS, Wright J, Brocklebank D, et al. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2) agonists bronchodilators in asthma. BMJ 2001; 323 (7318): 901-5
18. NICE. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. London: National Institute for Clinical Excellence, 2000
19. NICE. Inhaler devices for routine treatment of chronic asthma in older children (aged 5-15 years). London: National Institute of Clinical Excellence, 2002
20. BTS/SIGN. British guidelines on the management of asthma. Thorax 2003; 58 Suppl. 1: 1-94
21. ATS. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am J Respir Crit Care Med 1995; 152: S77-120
22. Jadad AR, Moore RA, Carrol D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17 (1): 1-12
23. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analyses detected by a simple graphical test. BMJ 1997; 315: 629-34
24. 3M Health Care. Four week safety and efficacy study of Airomir™ inhaler and CFC-salbutamol inhaler in children with asthma. Data on file, 1141-SILV, 3M Health Care, Loughborough, England, 1996
25. Ahlstrom H, Svenonius E, Svensson M. Treatment of asthma in pre-school children with inhalation of terbutaline in Turbuhaler compared with Nebuhaler. Allergy 1989; 44 (7): 515-8
26. Ahrens RC, Hendeles L, Clarke WR, et al. Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler: a bioassay using methacholine. Am J Respir Crit Care Med 1999; 160 (4): 1238-43
27. Ali N, Arshad H, Rastogi S, et al. Comparison of a breath-actuated inhaler with a standard inhaler and spacer device in asthma. Med Sci Res 1989; 17: 531-2
28. Anderson PB, Ståhl E, Hansen NCG. Terbutaline via Turbuhaler is effective in reversing metacholine-induced bronchoconstriction. J Clin Res 1998; 1: 49-54
29. Bateman ED, Joubert JR, Le Roux AM. et al. Therapeutic equivalence of MDI formulations of fenoterol with HFA or CFC propellants: a dose confirmation study in patients with asthma [abstract]. Eur Respir J 1997; 10 Suppl. 25: 240s
30. Baumgarten CR, Dorow P, Weber HH, et al. Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134-a in mild to moderate asthmatics. Respir Med 2000; 94 Suppl. B: S17-21
31. Bleecker ER, Tinkleman DG, Ramsdell J, et al. Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics. Chest 1998; 113 (2): 283-9
32. Bondesson E, Friberg K, Soliman S, et al. Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma. Respir Med 1998; 92 (2): 325-30
33. Borgström L, Derom E, Ståhl E, et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153 (5): 1636-40
34. Boye K. A comparison of fenoterol powder capsules and fenoterol metered dose spray in bronchial asthma. Eur J Respir Dis 1983; 64 Suppl. 130: 9-11
35. Bronsky E, Bucholtz GA, Busse WW, et al. Comparison of inhaled albuterol powder and aerosol in asthma. J Allergy Clin Immunol 1987; 79 (5): 741-7
36. Bronsky EA, Spector SL, Pearlman DS, et al. Albuterol aerosol versus albuterol Rotacaps in exercise-induced bronchospasm in children. J Asthma 1995; 32: 207-14
37. Bronsky E, Ekholm BP, Klinger NM, et al. Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane- 134a (HFA) albuterol. J Asthma 1999; 36 (1): 107-14
38. Chapman KR, Friberg K, Balter MS, et al. Albuterol via Turbuhaler versus albuterol via pressurized metered-dose inhaler in asthma. Ann Allergy Asthma Immunol 1997; 78 (1): 59-63
39. Cohen RM, Plescow WW, Webb DR, et al. Albuterol in HFA propellant (ALB-HFA) 180μg QID is comparable in safety and efficacy to albuterol in CFC propellant (ALB-CFC) 180μg QID in adolescent and adult patients with asthma. J Allergy Clin Immunol 1999; 103: S128
40. Colice GL, Klinger NM, Ekholm BP, et al. Proventil HFA prevents exercise-induced bronchoconstriction in children. J Asthma 1999; 36 (8): 671-6
41. Croner S, Hedenskog S, Kjellman NI, et al. Salbutamol by powder or spray inhalation in childhood asthma. Allergy 1980; 35 (7): 589-92
42. Custovic A, Taggart SC, Stuart A, et al. Efficacy of a new non-ozone depleting formulation for salbutamol. J Pharmacol Med 1995; 5: 161-8
43. Dirksen H, Groth S. Fenoterol inhalation powder as an alternative to treatment with the metered dose inhaler. Eur J Respir Dis 1983; 64 Suppl. 130: 48-53
44. Dockhorn R, Vanden Burgt JA, Ekholm BP, et al. Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma. J Allergy Clin Immunol 1995; 96 (1): 50-6
45. Dockhorn RJ, Wagner DE, Burgess GL, et al. Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin. Ann Allergy Asthma Immunol 1997; 79 (1): 85-8
46. Duncan D, Paterson IC, Harris D, et al. Comparison of the bronchodilator effects of salbutamol inhaled as a dry powder and by conventional pressurised aerosol. BF J Clin Pharmacol 1977; 4: 669-71
47. Ekstrom T, Andersson AC, Skedinger M, et al. Dose potency relationship of terbutaline inhaled via turbuhaler or via a pressurized metered dose inhaler. Ann Allergy Asthma Immunol 1995; 74: 328-32
48. Fuglsang G, Pedersen S. Comparison of a new multidose powder inhaler with a pressurized aerosol in children with asthma. Pediatr Pulmonol 1989; 7: 112-5
49. Geoffroy P, Lalonde RL, Ahrens R, et al. Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma. Ann Allergy Asthma Immunol 1999; 82 (4): 377-82
50. Giannini D, Di Franco A, Bacci E, et al. The protective effect of salbutamol inhaled using different devices on methacholine bronchostriction. Chest 2000; 117 (5): 1319-23
51. Goldberg J, Bohning W, Schmidt P, et al. Fenoterol hydrobromide delivered via HFA-MDI or CFC-MDI in patients with asthma: a safety and efficacy comparison. Respir Med 2000; 94 (10): 948-53
52. Golish J, Curtis-McCarthy P, McCarthy K, et al. Albuterol delivered by metered-dose inhaler (MDI), MDI with spacer and rotahaler device: a comparison of efficacy and safety. J Asthma 1998; 35 (4): 373-9
53. Haahtela T, Vidgren M, Nyberg A, et al. A novel multiple dose powder inhaler: salbutamol powder and aerosol give equal bronchodilatation with equal doses. Ann Allergy 1994; 72 (2): 178-82
54. Harris R, Rothwell RP. A comparison between aerosol and inhaled powder administration of fenoterol in adult asthmatics. N Z Med J 1981; 94 (697): 421-2
55. Hartely JP, Nogrady SG, Gibby OM, et al. Bronchodilator effects of dry salbutamol powder administered by Rotahaler. Br J Clin Pharmacol 1977; 4: 673-5
56. Hartley JPR, Nogrady SG, Seaton A. Long-term comparison of salbutamol powder with salbutamol aerosol in asthmatic out-patients. Br J Dis Chest 1979; 73: 271-6
57. Hawksworth R, Sykes AP, Bogolubov M, et al. Comparison of the bronchoprotective effect of single doses of albuterol/HFA 134a and albuterol/CFC against exercise induced bronchoconstriction. J Allergy Clin Immunol 1999; 103: S129
58. Hetzel MR, Clark CG. Comparison of salbutamol rotahaler with conventional pressurized aerosol. Clin Allergy 1997; 7: 563-8
59. Hindle M, Newton DAG, Chrystyn H. Dry powder inhalers are bioequivalent to metered-dose inhalers. Chest 1995; 107: 629-33
60. Hirsch T, Peter-Kern M, Koch R, et al. Influence of inspiratory capacity on bronchodilation via Turbuhaler or pressurized metered-dose inhaler in asthmaic children. Respir Med 1997; 91: 341-6
61. Hultquist C, Ahlstrom H, Kjellman NM, et al. A double-blind comparison between a new multi-dose powder inhaler (turbuhaler) and metered dose inhaler in children with asthma. Allergy 1989; 44: 467-70
62. Jackson L, Stahl E, Holgate ST. Terbutaline via pressurised metered dose inhaled (P-MDI) and turbuhaler in highly reactive asthmatic patients. Eur Respir J 1994; 7 (9): 1598-601
63. Johnsen CR, Weeke ER. Turbuhaler: a new device for dry powder terbutaline inhalation. Allergy 1988; 43 (5): 393-5
64. Kemp JP, Furukawa CT, Bronsky EA, et al. Albuterol treatment for children with asthma: a comparison of inhaled powder and aerosol. J Allergy Clin Immunol 1989; 83 (3): 697-702
65. Kemp JP, Hill MR, Vaughan LM, et al. Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler. Ann Allergy Asthma Immunol 1997; 79: 322-6
66. Kiviranta K. Fenoterol inhalation powder and aerosol in the treatment of asthma. Allergy 1985; 40 (4): 305-7
67. Kleerup EC, Tashkin DP, Cline AC, et al. Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Chest 1996; 109 (3): 702-7
68. Koskela T, Malmstrom K, Sairanen U, et al. Efficacy of salbutamol via Easyhaler unaffected by low inspiratory flow. Respir Med 2000; 94 (12): 1229-33
69. Kou M, Kumana CR, Lauder IJ, et al. Bronchodilator responses to salbutamol using diskhaler versus metered-dose inhaler. J Asthma 1998; 35 (6): 505-11
70. Laberge S, Spier S, Drblik SP, et al. Comparison of inhaled terbutaline administered by either the turbuhaler dry powder or a metered-dose inhaler with spacer in preschool children with asthma. J Pediatr 1994; 124 (5 Pt 1): 815-7
71. Langley SJ, Masterton CM, Batty EP, et al. Comparison of single doses of HFA-134a propellant and CFC salbutamol in mild to moderate asthmatic patients. Eur Respir J 1998; 28: 67S
72. Langley SJ, Sykes AP, Batty EP, et al. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. Ann Allergy Asthma Immunol 2002: 88 (5): 488-93
73. Latimer KM, Roberts R, Dolovich J, et al. Salbutamol: comparison of bronchodilating effect of inhaled powder and aerosol in asthmatic subjects. CMAJ 1982; 127: 857-9
74. Leclerc V, Thebault JJ, Iacono P, et al. Dose-response to fenoterol MDI with non-CFC propellant HFA134a is equivalent to CFC-MDI in patients with asthma [abstract]. For Respir J 1997; 25: 239s
75. Löfdahl CG, Andersson L, Bondesson E, et al. Differences in bronchodilating potency of salbutamol in Turbuhaler as compared with pressurized metered-dose inhaler formulation in patients with reversible airway obstruction. Eur Respir J 1997; 10: 2474-8
76. Lumry W, Noveck R, Weinstein S, et al. Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma. Ann Allergy Asthma Immunol 2001; 86 (3): 297-303
77. Maesen FP, Smeets JJ, Bersen R, et al. Ipratropium bromide (Atrovent) as inhalation powder: a double-blind study of comparison with ipratropium as a pressure aerosol in patients with reversible airways obstruction. Allergy 1986; 41 (1): 37-42
78. Maesen FPV, van Noord JA, Smeets JJ, et al. Dose-range finding study comparing a new soft mist inhaler with a conventional metered dose inhaler (MDI) to deliver fenoterol in patients with asthma [abstract]. Eur Respir J 1997; 25: 128s
79. Marta D, Dutu S, Bistriceanu G, et al. Comparison of the bronchodilating effect of salbutamol delivered via a multidose powder inhaler versus a conventional metered dose inhaler [abstract]. Eur Respir J 1997; 25: 238s
80. Mathieu M, Goldman M, Lellouche N, et al. Kinetics of action of salbutamol inhaled from a metered dose inhaler (MDT) and a "diskhaler". Eur J Clin Pharmacol 1992; 42 (4): 435-8
81. Mellen A, Arvidsson P, Palmqvist M, et al. Equivalent bronchodilation with salbutamol given via pMDI or turbuhaler. Am J Respir Crit Care Med 1999; 159 (5 Pt 1): 1663-5
82. Middle MV, Terblanche J, Perrin VL, et al. Bronchodilating effects of salbutamol from a novel inhaler Airmax. Respir Med 2002; 96 (7): 493-8
83. Mitchell CA, Thompson PJ, Ruffin RE, et al. Terbutaline via Turbuhaler and pMDI: a study of the relative dose response in patients with asthma. Aust N Z J Med 1998; 261-3
84. Morice AH, Peake MD, Allen MB, et al. Evaluation of a novel salbutamol dry powder inhaler: clinical equivalence to a standard metered dose inhaler and in-use stability [abstract]. Br J Clin Pharmacol 1996; 42: 658P
85. Nelson H, Kemp J, Bieler S, et al. Comparative efficacy and safety of albuterol sulfate spires inhaler and albuterol metered-dose inhaler in asthma. Chest 1999; 115: 329-35
86. Newhouse MT, Nantel NP, Chambers CB, et al. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest 1999; 115 (4): 952-6
87. Newman SP, Clarke SW. Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler. Chest 1993; 103 (5): 1442-6
88. Nieminen NM, Vidgren M, Laurikainen K,.et al. Easyhaler, a novel multiple dose powder inhale: clinically equivalent to salbutamol metered dose inhaler and easier to use. Respiration 1994; 61 (1): 37-41
89. O'Callaghan C, Everard ML, Russell RIR, et al. Efficacy and safety of salbutamol delivered by a novel multidose dry powder inhaler (DPI) and a pressurized metered dose inhaler (MDI) in paediatric asthma [abstract]. Eur Respir J 1997; 16: 126s
90. O'Callaghan C, Everard ML, Bush A, et al. Salbutamol dry power inhaler: efficacy, tolerability, and acceptability study. Pediatr Pulmonol 2002; 33 (3): 189-93
91. Osterman K, Norborg AM, Stahl E. A multiple dose powder inhaler (Turbuhaler) compared with a conventional aerosol. Allergy 1989; 44: 294-7
92. Osterman K, Stahl E, Kallen A. Bricanyl turbuhaler in the treatment of asthma: a six week multi-centre study carried out in Sweden, the United Kingdom, Denmark, Norway and Finland. Eur Respir J 1991; 4: 175-9
93. Parameswaran KN, Inman MD, Ekholm BP, et al. Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta-2 agonists. Am J Respir Crit Care Med 1999; 160: 354-7
94. Persson G, Gruvstad E, Stahl E. A new multiple dose powder inhaler, (Turbuhaler), compared with a pressurized inhaler in a study of terbutaline in asthmatics. Eur Respir J 1988; 1: 681-4
95. Pover GM, Langdon CG, Jones SR, et al. Evaluation of a breath operated powder inhaler. J Int Med Res 1988; 16 (3): 201-3
96. Ramsdell JW, Colice GL, Ekholm BP, et al. Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. Ann Allergy Asthma Immunol 1998; 81 (6): 593-9
97. Randell J, Hamalainen KM, Leinonen M, et al. Salbutamol via Easyhaler multidose dry powder inhaler produces equivalent relief of histamine-induced bronchoconstriction to salbutamol via pressurised metered-dose inhaler. Clin Drug Invest 2000; 19 (5): 355-41
98. Ramsdell JW, Klinger NM, Ekholm BP, et al. Safety of long-term treatment with HFA albuterol. Chest 1999; 115 (4): 945-51
99. Razzouk H, dos Santos L, Giudicelli J, et al. A comparison of the bronchodilatory effect of 50 and 100 ug salbutamol via turbuhaler and 100 ug salbutamol via pressurized metered dose inhaler in children with stable asthma. Int J Pharm 1999; 180: 169-75
100. Revyakina VR, Terpstra GK. Salbutamol delivered via a new multi-dose dry powder inhaler is as safe and efficacious as a pressurised metered dose inhaler in children aged 6-12 years. ERJ 2002; 20: 501s
101. Ruffin R, Mitchell CTP, Harle D, et al. A placebo controlled comparison of the dose-response effects of salbutamol sulphate in chlorofluorocarbon (CFC) vs hydrofluoroalkane (HFA-134a) propellants in asthmatics [abstract]. Am J Respir Crit Care Med 1995; 151: A58
102. Salat D, Popov D, Sykes AP. Equivalence of salbutamol 200ug four times daily propelled by propellants 11 and 12 or HFA 134-a in mild to moderate asthmatics. Respir Med 2000: 94 Suppl. B: S22-S8
103. Salorinne Y, Siren R. Ventilation effects of fenoterol powder and freon-propelled aerosol in patients with asthma. Eur J Respir Dis Suppl 1983; 130: 6-8
104. Selroos O, Lofroos AB, Pietinalho A, et al. Comparison of terbutaline and placebo from a pressurised metered dose inhaler and a dry powder inhaler in a subgroup of patients with asthma. Thorax 1994; 49: 1228-30
105. Seppala OP, Kari E, Perttunen K, et al. Dose-response of salbutamol inhaled from a new metered dose powder inhaler compared with placebo and a metered dose inhaler with a spacer [abstract]. Eur Respir J 1997; 10: 238s
106. Seppala OP, Kari E, Elo E, et al. Comparison of the bronchodilating efficacies of a novel salbutamol metered dose powder inhaler and a pressurised metered dose aerosol with a spacer. Arzneimittelforschung 1998; 48 (9): 919-23
107. Seppala OP, Herrala J, Hedman J, et al. The bronchoprotective efficacy of salbutamol inhaled from a new metered-dose powder inhaler compared with a conventional pressurized metered-dose inhaler connected to a spacer. Respir Med 1998; 92: 578-83
108. Shapiro G, Bronsky E, Murray A, et al. Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma. Arch Pediatr Adolesc Med 2000; 154 (12): 1219-25
109. Shapiro GS, Klinger NM, Ekholm BP, et al. Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons- 11/12 (CFC) albuterol in children with asthma. J Asthma 2000; 37 (8): 667-75
110. Silvasti M, Laurikainen K, Nieminen M, et al. Single dose comparison between a novel multiple dose powder inhaler and a conventional metered dose inhaler in asthmatic patients. Acta Ther 1993; 19: 125-35
111. Svedmyr N, Lofdahl CG, Svedmyr K. The effect of powder aerosol compared to pressurized aerosol. Eur J Respir Dis 1982; 63 Suppl. 119: 81-8
112. Svenonius E, Arborelius M, Wiberg R, et al. A comparison of terbutaline inhaled by turbuhaler and by a chlorofluorocarbon (CFC) inhaler in children with exercise-induced asthma. Allergy 1994; 49: 408-12
113. Taggart SC, Custovic A, Richards DH, et al. GR106642X: a new, non-ozone depleting Propellant for inhalers. BMJ 1995; 310: 1639-40
114. Tammivaara R, Aalto E, Lehtonen K, et al. Comparison of a novel salbutamol multidose powder inhaler with a salbutamol metered dose inhaler in patients with asthma. Curr Ther Res 1997; 58 (10): 734-44
115. Thompson P. Cumulative dose-response study of Airomir™ (salbutamol sulphate in CFC-free system) versus CFC salbutamol sulphate and HFA- 134a placebo in patients with asthma. Br J Clin Pract 1995; 49 Suppl. 79: 31-2
116. Tukianen H, Terho EO. Comparison of inhaled salbutamol powder and aerosol in asthmatic patients with low peak expiratory flow level. Eur J Clin Pharmacol 1985; 27 (6): 645-7
117. van Noord JA, Smeets JJ, Creemers JP, et al. Delivery of fenoterol via Respimat, a novel 'soft mist' inhaler a randomised, double-blind (within device), placebo-controlled, cross-over, dose-ranging study in asthmatic patients. Respiration 2000; 67 (6): 672-8
118. Vidgren M, Silvasti M, Korhonen P, et al. Clinical equivalence of a novel multiple dose powder inhaler versus a conventional metered dose inhaler on bronchodilating effects of salbutamol. Arzneimittelforschung 1995; 45 (1): 44-7
119. Villiger B, Schwarz F. Comparison of inhaled terbutaline either via MDI or via a new DPI Turbuhaler [abstract]. Eur Respir J 1990; 3: 94s
120. Waterhouse JC, Simmons JL, Wray H, et al. Comparative assessment of a new breath-actuated inhaler in patients with reversible airways obstruction. Respiration 1992; 59: 155-8
121. Zainudin BMZ, Biddiscombe M, Tolfree SEJ, et al. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurized metered dose inhaler, as a dry powder, and as a nebulized solution. Thorax 1990; 45: 469-73
122. Vidgren M, Paronen P, Vidgren P, et al. In vivo evaluation of the new multiple dose powder inhaler and the rotahaler using the gamma scintigraphy. Acta Pharm Nord 1990; 2 (1): 3-10
123. Vincken W, Aumann J, Radermecker M, et al. Comparison of pharmacodynamics, efficacy and safety of fenoterol inhaled from a novel pocket-sized inhaler and from a metered-dose inhaler (MDI) [abstract]. Eur Respir J 1997; 10: 239s
124. Hughes DA, Woodcock A, Walley T. Review of therapeutically equivalent alternatives to short acting beta (2) adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers. Thorax 1999; 54 (12): 1087-92
125. Jones B, Jarvis P, Lewis JA, et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313 (7048): 36-9
126. Wong BJ, Hargreave FE. Bioequivalence of metered-dose inhaled medications. J Allergy Clin Immunol 1993; 92: 373-9
127. Lipworth BJ, Clark DJ. Lung deposition of salbutamol given by breath activated pressurized aerosol and dry powder inhalers devices. Pulm Pharmacol Ther 1997; 10 (4): 211-4
128. Clark DJ, Lipworth BJ. Dose-response of inhaled drugs in asthma: an update. Clin Pharmacokinet 1997; 32 (1): 58-74
129. Cleophas TJ. Carry-over biases in clinical pharmacology. Eur J Clin Chem Clin Biochem 1993; 31 (12): 803-9
130. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trails: the CONSORT statement. JAMA 1996; 276: 637-9